Dyadic International, Inc. is a global biotechnology company dedicated to advancing drug development through its proprietary C1 expression system. The company aims to help drug developers and manufacturers bring biologic drugs to market more efficiently, focusing on improving access and reducing costs for patients. Dyadic's market focus includes human health, animal health, and cultured meat, all aimed at producing next-generation proteins to enhance global health.
Dyadic has made significant strides in the biotechnology sector, leveraging its innovative microbial platforms to revolutionize biologic vaccine and drug production. The company's impact is evident in its contributions to making life-saving treatments more accessible and affordable. Dyadic's evolution from an industrial textiles company to a leader in life sciences underscores its commitment to scientific advancement and public health.
